Last reviewed · How we verify
Revlimid
At a glance
| Generic name | Revlimid |
|---|---|
| Also known as | Lenalidomide, CC-5013, lénalidomide, lenalidomide, Gemzar |
| Sponsor | M.D. Anderson Cancer Center |
| Target | Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Myelodysplastic syndrome
Common side effects
- Fatigue
- Diarrhea
- Asthenia
- Anemia
- Constipation
- Peripheral edema
- Neutropenia
- Back pain
- Nausea
- Insomnia
- Pyrexia
- Infection
Serious adverse events
- Neutropenia
- Thrombocytopenia
- Pneumonia
- DVT
- Dyspnea
- Hyperglycemia
- Leukopenia
- Lymphopenia
- Cataract
- Rash
Key clinical trials
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (PHASE1)
- Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (PHASE3)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE1)
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Revlimid CI brief — competitive landscape report
- Revlimid updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI